BDR Pharmaceutical launches Zisavel capsules to treat invasive aspergillosis, mucormycosis

BDR Pharmaceutical announced the launch of the first-of-itskind generic drug, Zisavel Capsules, for the treatment of invasive aspergillosis and mucormycosis. Zisavel belongs to the family of isavuconazole, a class of medications called
azole antifungals. Isavuconazole plays an important role in the treatment of invasive aspergillosis.
The product will be available in 100 mg capsules and is the first line of treatment for the aforementioned fungal infections. The price of the generic drug will be Rs 7992, for seven capsules which is one-third the
600 Industry Professionals BDR Pharmaceutical launches Zisavel capsules to treat invasive aspergillosis, mucormycosis, ET HealthWorld cost of present therapy available by innovators. The company aims to reduce the cost of therapy for invasive fungal diseases with isavuconazole to be on par with voriconazole and posaconazole (new-generation anti-fungal agents), making it more accessible to patients who are unable to afford it currently.
According to the statistics, the incidence rate of mucormycosis varies globally from 0.005 to 1.7 per million people. In India, the prevalence of mucormycosis is estimated at 140 per million people, 70–80 times higher
than in any developed country. With regards to Aspergillosis cases in India, the annual incidence of invasive Aspergillosis is estimated at 2,50,900 cases, including chronic obstructive pulmonary disease, lung cancer, leukaemia, lymphoma, or transplantation. In the year 2020, invasive aspergillosis cases will have accounted for approximately 2,360 deaths. The global antifungal drugs market size was valued at $15.80 billion in
2022 and is projected to witness a compound annual growth rate (CAGR) of 3.74 per cent from 2023 to 2030. The growing prevalence of fungal infections such as aspergillosis and candidiasis is one of the key factors
propelling the market. The India anti-fungal drugs market is estimated to be valued at $ 1.56273 bn in 2021 and is expected to exhibit a CAGR of 10.49 per cent over the forecast period (2021-2030). Talking about the need for and accessibility of the drugs Raheel Shah, Director, Business Development, BDR Group, said, “The burden of
fungus diseases varies substantially based on geography, type of

infection, severity of the disease, and various other socioeconomic factors. Isavuconazole will play an important role in controlling the infection and overall life expectancy

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!